Prenatal Programming of Metabolic Syndrome in the Common Marmoset Is Associated With Increased Expression of 11β-Hydroxysteroid Dehydrogenase Type 1

被引:50
|
作者
Nyirenda, Moffat J. [1 ]
Carter, Roderick [1 ]
Tang, Justin I. [1 ]
de Vries, Annick [1 ]
Schlumbohm, Christina [2 ]
Hillier, Stephen G. [3 ]
Streit, Frank [4 ]
Oellerich, Michael [4 ]
Armstrong, Victor W. [4 ]
Fuchs, Eberhard [2 ]
Seckl, Jonathan R. [1 ]
机构
[1] Univ Edinburgh, Endocrinol Unit, Queens Med Res Inst, Edinburgh EH8 9YL, Midlothian, Scotland
[2] Leibniz Inst Primate Res, Clin Neurobiol Lab, German Primate Ctr, Gottingen, Germany
[3] Univ Edinburgh, MRC, Reprod Sci Unit, Queens Med Res Inst, Edinburgh EH8 9YL, Midlothian, Scotland
[4] Univ Gottingen, Dept Clin Chem, Gottingen, Germany
关键词
TISSUE-SPECIFIC DYSREGULATION; GLUCOCORTICOID METABOLISM; INSULIN-RESISTANCE; GLUCOSE-METABOLISM; ADIPOSE-TISSUE; OBESITY; CORTISOL; RATS; DISEASE; MICE;
D O I
10.2337/db09-0873
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-Recent studies in humans and animal models of obesity have shown increased adipose tissue activity of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1), which amplifies local I issue glucocorticoid concentrations. The reasons for this 11 beta-HSD1 dystegulation are unknown. Here, we tested whether 11 beta-HSD1 expression, like the metabolic syndrome, is "programmed" by prenatal environmental events in a nonhuman primate model, the common marmoset monkey. RESEARCH DESIGN AND METHODS-We used a "fetal programming" paradigm where brief antenatal exposure to glucocorticoids leads to the metabolic syndrome in the offspring. Pregnant marmosets were given the synthetic glucocorticoid dexamethasone orally for 1 week in either early or late gestation, or they were given vehicle. Tissue 11 beta-HSD1 and glucocorticoid receptor mRNA expression were examined in the offspring at 4 and 24 months of age. RESULTS-Prenatal dexamethasone administration, selectively during late gestation, resulted in early and persistent elevations in 11 beta-HSD1 mRNA expression and activity in the liver, pancreas, and subcutaneous-but not visceral-fat. The increase in 11 beta-HSD1 occurred before animals developed obesity or overt features of the metabolic syndrome. In contrast to rodents, in utero dexamethasone exposure did not alter glucocorticoid receptor expression in metabolic tissues in marmosets. CONCLUSIONS-These data suggest that long-term upregulation of 11 beta-HSD1 in metabolically active tissues may follow prenatal "stress" hormone exposure and indicates a novel mechanism for fetal origins of adult obesity and the metabolic syndrome. Diabetes 58:2873-2879, 2009
引用
收藏
页码:2873 / 2879
页数:7
相关论文
共 50 条
  • [21] Regulatory Effect of Common Promoter Polymorphisms on the Expression of the 11β-Hydroxysteroid Dehydrogenase Type 1 Gene
    Ku, Yun Hyi
    Koo, Bo Kyung
    Kwak, Soo Heon
    Cho, Young Min
    Shin, Hyoung Doo
    Lee, Hong Kyu
    Kim, Yeonjung
    Choi, Jung-Won
    Oh, Bermseok
    Park, Kyong Soo
    HORMONE RESEARCH, 2009, 72 (01) : 25 - 32
  • [22] Adipose tissue expression of 11β-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity
    Espindola-Antunes, Daniela
    Kater, Claudio E.
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2007, 51 (08) : 1397 - 1403
  • [23] Reduced Expression of 11β-Hydroxysteroid Dehydrogenase Type 2 in Preeclamptic Placentas Is Associated With Decreased PPARγ but Increased PPARα Expression
    He, Ping
    Chen, Zhaoguang
    Sun, Qianqian
    Li, Yuan
    Gu, Hang
    Ni, Xin
    ENDOCRINOLOGY, 2014, 155 (01) : 299 - 309
  • [24] Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome
    Mariniello, Barbara
    Ronconi, Vanessa
    Rilli, Silvia
    Bernante, Paolo
    Boscaro, Marco
    Mantero, Franco
    Giacchetti, Gilberta
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 155 (03) : 435 - 441
  • [25] Increased expression of 11beta-hydroxysteroid dehydrogenase Type 1 in subcutaneous adipose tissue in HIV-associated lipodystrophy
    Sutinen, JP
    Kannisto, K
    Korsheninnikova, E
    Nyman, T
    Hamsten, A
    Wake, D
    Walker, B
    Yki-Järvinen, H
    DIABETOLOGIA, 2003, 46 : A212 - A212
  • [26] Mechanisms of disease:: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome
    Tomlinson, JW
    Stewart, PM
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2005, 1 (02): : 92 - 99
  • [27] Association between 11β-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population
    Dujic, Tanja
    Bego, Tamer
    Mlinar, Barbara
    Semiz, Sabina
    Malenica, Maja
    Prnjavorac, Besim
    Ostanek, Barbara
    Marc, Janja
    Causevic, Adlija
    BIOCHEMIA MEDICA, 2012, 22 (01) : 76 - 85
  • [28] Evolution of 11β-hydroxysteroid dehydrogenase-type 1 and 11β-hydroxysteroid dehydrogenase-type 3
    Baker, Michael E.
    FEBS LETTERS, 2010, 584 (11) : 2279 - 2284
  • [29] Mechanisms of Disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome
    Jeremy W Tomlinson
    Paul M Stewart
    Nature Clinical Practice Endocrinology & Metabolism, 2005, 1 : 92 - 99
  • [30] Metabolic syndrome without obesity:: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice
    Paterson, JM
    Morton, NM
    Fievet, C
    Kenyon, CJ
    Holmes, MC
    Staels, B
    Seckl, JR
    Mullins, JJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (18) : 7088 - 7093